These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 22885136)

  • 21. Modeling disease progression via multi-task learning.
    Zhou J; Liu J; Narayan VA; Ye J;
    Neuroimage; 2013 Sep; 78():233-48. PubMed ID: 23583359
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Plasma neuronal exosomes serve as biomarkers of cognitive impairment in HIV infection and Alzheimer's disease.
    Pulliam L; Sun B; Mustapic M; Chawla S; Kapogiannis D
    J Neurovirol; 2019 Oct; 25(5):702-709. PubMed ID: 30610738
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inexpensive, non-invasive biomarkers predict Alzheimer transition using machine learning analysis of the Alzheimer's Disease Neuroimaging (ADNI) database.
    Beltrán JF; Wahba BM; Hose N; Shasha D; Kline RP;
    PLoS One; 2020; 15(7):e0235663. PubMed ID: 32716914
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sensitivity of a Preclinical Alzheimer's Cognitive Composite (PACC) to amyloid β load in preclinical Alzheimer's disease.
    Bransby L; Lim YY; Ames D; Fowler C; Roberston J; Harrington K; Snyder PJ; Villemagne VL; Salvado O; Masters CL; Maruff P
    J Clin Exp Neuropsychol; 2019 Aug; 41(6):591-600. PubMed ID: 30924399
    [No Abstract]   [Full Text] [Related]  

  • 25. Erlangen Score Predicts Cognitive and Neuroimaging Progression in Mild Cognitive Impairment Stage of Alzheimer's Disease.
    Skillbäck T; Kornhuber J; Blennow K; Zetterberg H; Lewczuk P;
    J Alzheimers Dis; 2019; 69(2):551-559. PubMed ID: 31104027
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Application of Digital Cognitive Biomarkers for Alzheimer's Disease: Identifying Cognitive Process Changes and Impending Cognitive Decline.
    Bock JR; Hara J; Fortier D; Lee MD; Petersen RC; Shankle WR
    J Prev Alzheimers Dis; 2021; 8(2):123-126. PubMed ID: 33569557
    [TBL] [Abstract][Full Text] [Related]  

  • 27. NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease.
    Jack CR; Bennett DA; Blennow K; Carrillo MC; Dunn B; Haeberlein SB; Holtzman DM; Jagust W; Jessen F; Karlawish J; Liu E; Molinuevo JL; Montine T; Phelps C; Rankin KP; Rowe CC; Scheltens P; Siemers E; Snyder HM; Sperling R;
    Alzheimers Dement; 2018 Apr; 14(4):535-562. PubMed ID: 29653606
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Longitudinal Basal Forebrain Degeneration Interacts with TREM2/C3 Biomarkers of Inflammation in Presymptomatic Alzheimer's Disease.
    Schmitz TW; Soreq H; Poirier J; Spreng RN
    J Neurosci; 2020 Feb; 40(9):1931-1942. PubMed ID: 31915256
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Amyloid-β Positivity Predicts Cognitive Decline but Cognition Predicts Progression to Amyloid-β Positivity.
    Elman JA; Panizzon MS; Gustavson DE; Franz CE; Sanderson-Cimino ME; Lyons MJ; Kremen WS;
    Biol Psychiatry; 2020 May; 87(9):819-828. PubMed ID: 32067693
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Utility of combinations of biomarkers, cognitive markers, and risk factors to predict conversion from mild cognitive impairment to Alzheimer disease in patients in the Alzheimer's disease neuroimaging initiative.
    Gomar JJ; Bobes-Bascaran MT; Conejero-Goldberg C; Davies P; Goldberg TE;
    Arch Gen Psychiatry; 2011 Sep; 68(9):961-9. PubMed ID: 21893661
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Predicting progression and cognitive decline in amyloid-positive patients with Alzheimer's disease.
    Dansson HV; Stempfle L; Egilsdóttir H; Schliep A; Portelius E; Blennow K; Zetterberg H; Johansson FD;
    Alzheimers Res Ther; 2021 Sep; 13(1):151. PubMed ID: 34488882
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Alzheimer's Disease Neuroimaging Initiative 2 Biomarker Core: A review of progress and plans.
    Kang JH; Korecka M; Figurski MJ; Toledo JB; Blennow K; Zetterberg H; Waligorska T; Brylska M; Fields L; Shah N; Soares H; Dean RA; Vanderstichele H; Petersen RC; Aisen PS; Saykin AJ; Weiner MW; Trojanowski JQ; Shaw LM;
    Alzheimers Dement; 2015 Jul; 11(7):772-91. PubMed ID: 26194312
    [TBL] [Abstract][Full Text] [Related]  

  • 33.
    Song YN; Li JQ; Tan CC; Wang HF; Tan MS; Cao XP; Yu JT; Tan L;
    Front Neurosci; 2019; 13():455. PubMed ID: 31156362
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Potential neuroimaging biomarkers of pathologic brain changes in Mild Cognitive Impairment and Alzheimer's disease: a systematic review.
    Ruan Q; D'Onofrio G; Sancarlo D; Bao Z; Greco A; Yu Z
    BMC Geriatr; 2016 May; 16():104. PubMed ID: 27184250
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparing progression biomarkers in clinical trials of early Alzheimer's disease.
    Cullen NC; Zetterberg H; Insel PS; Olsson B; Andreasson U; ; Blennow K; Hansson O; Mattsson-Carlgren N
    Ann Clin Transl Neurol; 2020 Sep; 7(9):1661-1673. PubMed ID: 32779869
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Development of biomarkers to chart all Alzheimer's disease stages: the royal road to cutting the therapeutic Gordian Knot.
    Hampel H; Lista S; Khachaturian ZS
    Alzheimers Dement; 2012 Jul; 8(4):312-36. PubMed ID: 22748938
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Alzheimer Disease Signature Neurodegeneration and APOE Genotype in Mild Cognitive Impairment With Suspected Non-Alzheimer Disease Pathophysiology.
    Schreiber S; Schreiber F; Lockhart SN; Horng A; Bejanin A; Landau SM; Jagust WJ;
    JAMA Neurol; 2017 Jun; 74(6):650-659. PubMed ID: 28319241
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association between Cerebrospinal Fluid Biomarkers for Alzheimer's Disease, APOE Genotypes and Auditory Verbal Learning Task in Subjective Cognitive Decline, Mild Cognitive Impairment, and Alzheimer's Disease.
    Mandecka M; Budziszewska M; Barczak A; Pepłońska B; Chodakowska-Żebrowska M; Filipek-Gliszczyńska A; Nesteruk M; Styczyńska M; Barcikowska M; Gabryelewicz T
    J Alzheimers Dis; 2016 Jul; 54(1):157-68. PubMed ID: 27472875
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CSF complement 3 and factor H are staging biomarkers in Alzheimer's disease.
    Hu WT; Watts KD; Tailor P; Nguyen TP; Howell JC; Lee RC; Seyfried NT; Gearing M; Hales CM; Levey AI; Lah JJ; Lee EK;
    Acta Neuropathol Commun; 2016 Feb; 4():14. PubMed ID: 26887322
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cerebrospinal fluid α-synuclein predicts neurodegeneration and clinical progression in non-demented elders.
    Li JQ; Bi YL; Shen XN; Wang HF; Xu W; Tan CC; Dong Q; Wang YJ; Tan L; Yu JT;
    Transl Neurodegener; 2020 Nov; 9(1):41. PubMed ID: 33228804
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.